Skip to main content
. 2019 Dec;8(6):895–906. doi: 10.21037/tlcr.2019.11.17

Figure 2.

Figure 2

Survival analysis by TIM-3 level on TILs and tumor cells. High level of TIM-3 on TILs indicated shorter RFS (C: RFS 1.800 years, 95% CI, 1.230–2.370 vs. 0.870 years, 95% CI, 0.212–1.528, P=0.048) and OS (D: OS 2.960 years, 95% CI, 2.268–3.652 vs. 1.080 years, 95% CI, 0.228–1.932, P=0.034). TIM-3 level on tumor cells showed no correlation with survival (A: RFS 1.760 years, 95% CI, 1.246–2.274 vs. 0.760 years, 95% CI, 0.497–1.023, P=0.622) (B: OS 2.790 years, 95% CI, 1.970–3.610 vs. 1.043 years, 95% CI, 0.000–3.505, P=0.615). In stage I–II patients: E: RFS 3.210 vs. 1.080 years, P=0.008; F: OS 3.440 vs. 1.080 years, P=0.001.